Medicine
FDA news, research, studies, and rapid health briefings. Visit Viral Vitalism for plain-language context, evidence boundaries, and related signals.
News cycle
FDA extended one North American coral snake antivenin lot through December 31, 2026, highlighting an emergency-medicine supply chain held together by stability data.
Why now
The extension keeps a critical emergency product available in the absence of a licensed U.S. alternative.
FDA's July advisory meeting covers BPC-157, Semax, Epitalon-related substances, MOTS-c, TB-500, KPV, DSIP/emideltide, and other peptide-related bulk substances popular in longevity circles.
Why now
The FDA calendar puts several longevity-clinic peptide favorites into a formal public regulatory review window.
FDA is investigating rare catastrophic neurologic outcomes after sevoflurane anesthesia in patients of maternal Venezuelan ancestry, with a mitochondrial variant reported in some cases.
Why now
FDA's alert creates an immediate clinician-awareness and family-history question before anesthesia in a specific ancestry-linked risk context.
Certain Omnipod Pods may leak insulin because of a cannula tear, creating under-delivery risk that can lead to hyperglycemia or diabetic ketoacidosis.
Why now
FDA's Class I classification makes this an urgent patient-safety story for insulin-dependent diabetes users who may have affected Pods.
Casgevy's label expansion moves CRISPR-based treatment access earlier for some children with sickle cell disease or transfusion-dependent beta thalassemia, but the treatment remains intensive and transplant-like.
Why now
The age expansion moves CRISPR medicine from teens and adults into much younger children for two severe inherited blood disorders.
FDA says unapproved human cell and tissue products marketed online may pose serious risks, including reports of patient deaths after use.
Why now
The gray-market regenerative medicine boom needs a clean evidence boundary alongside real cell and gene therapy breakthroughs.
Larimar submitted the first module of a rolling BLA for nomlabofusp, a frataxin-replacement candidate for Friedreich's ataxia.
Why now
Friedreich's ataxia has few disease-modifying options and the program is moving from biomarker signal toward FDA review.
Sandoz and Hybio said FDA accepted generic tirzepatide applications, opening a new phase in the long access fight around Mounjaro and Zepbound.
Why now
GLP-1 attention is shifting from efficacy to access, patents, pricing, supply, and generic strategy.
FDA advisers will review whether several popular peptides should be allowed for certain pharmacy compounding uses, while FDA materials flag limited human evidence and potential safety or quality concerns.
Why now
The peptide gray market just got a real FDA spotlight: BPC-157, TB-500, MOTS-c, Semax, and Epitalon are heading into a public review.
Regenxbio says FDA aligned on a path to resubmit Navsunli/RGX-121 for accelerated approval review, but the therapy is not approved.
Why now
FDA has reopened a filing path after the program's regulatory outlook had narrowed.
A new FDA draft guidance and recent reversals suggest the biggest bottleneck in gene therapy may no longer be the science alone. It may be the approval process itself.
Why now
Draft guidance and recent reversals suggest the rare-disease rulebook is changing in real time.
Research map
Research records connected to this topic through topic tags, source records, and timeline events.
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No selling your information. Unsubscribe anytime.
By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.
